Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Comorbid chronic inflammatory diseases influence the prognosis of alopecia areata, according to study findings.

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including an | Immunology ...

In a new JAMA Dermatology study, scientists at King's College London found that changes in two parts of the genome work ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Dallas Cowboys Cheerleader Armani Latimer brought awareness to alopecia on "My Cause, My Cleats" night. ARLINGTON, Texas — It's an annual celebration for the NFL: “My Cause, My Cleats.” The night is ...

Everyone’s alopecia areata is different. Even though everyone who has it experiences hair loss, it may have many variations, including where, when, and how often you lose your hair. Alopecia ...

The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.